X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds from the offering to advance the clinical development of its product candidate APVO436 for treating acute myeloid leukemia.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 15, 2024
Details:
The company intends to use the net proceeds from the offering for the continued clinical development of its product candidate APVO436 for the treatment of acute myeloid leukemia.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2024
Details:
ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells. It is being evaluated for the treatment of solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alligator Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 04, 2023
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR drug candidate. The Company previously reported positive Phase 1b expansion trial results in AML and is planning to initiate Phase 2 trials in relapsed/refractory and frontline patients in 2H23 and 1H24 respectively.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
Through the aquisition, XOMA gains the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics.
Lead Product(s): Coagulation Factor IX (recombinant)
Therapeutic Area: Genetic Disease Product Name: Ixinity
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
ALG.APV-527 is a bispecific conditional 4-1BB agonist, actuvates upon simultaneous binding to 4-1BB and 5T4. 4-1BB has the ability to stimulate the antitumor-specific T cells and NK cells and 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors.
Lead Product(s): ALG.APV-527
Therapeutic Area: Oncology Product Name: ALG.APV-527
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Alligator Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR currently in Phase 1b development in a multi-center, multi-cohort trial designed to evaluate safety, tolerability and efficacy in combination therapy and monotherapy for patients with AML.
Lead Product(s): APVO436,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to redirect immune system of patient to destroy leukemia cells expressing target CD123 molecule on their surface, has been engineered using Aptevo's proprietary and enabling bioengineering methods.
Lead Product(s): APVO436
Therapeutic Area: Oncology Product Name: APVO436
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
